The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...

On 9 December 2025, Relation Therapeutics announced a multi-program collaboration with Novartis, securing US$55 million in ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...

Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario’s new ...

Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 ...

Novartis has struck a $1.7 billion collaboration with Relation Therapeutics to use AI-driven drug discovery and human tissue data to develop novel treatments for atopic diseases including eczema, ...

New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...

Relation Therapeutics Ltd. will collaborate with Novartis AG in a $1.7 billion deal to develop multiple programs to find and advance targets for treating atopic diseases caused by immune dysregulation ...

Novartis operates globally in pharmaceuticals, focusing on therapeutic development, clinical research, and manufacturing, ...

Privately-held UK biotech Relation Therapeutics has announced a multi-program, strategic collaboration with Swiss pharma giant Novartis to discover and advance novel targets for atopic diseases.

Since launching in 2024, Novartis Canada is proud to have awarded over $1.2 million in funding through the Health Equity Initiative to drive meaningful and sustainable projects that will support ...